Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Dysken

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
JAMA|May 11, 1979
Drug interaction between ascorbic acid and fluphenazineM W Dysken, R J Cumming, R A Channon, et al.
Journal of Geriatric Psychiatry and Neurology|January 1, 1990
Hydergine treatment and psychophysiological measures in primary degenerative dementiaM A Kuskowski, G Morley, S M Malone, et al.
Psychopharmacology Bulletin|January 1, 1983
Neuroleptic concentrations in schizophrenic patients: measurements by radioreceptor assay and gas chromatographyJ I Javaid, J M Davis, M W Dysken, et al.
Hospital & Community Psychiatry|November 1, 1988
A multidisciplinary approach to primary degenerative dementiaA Frances, M W Dysken, R Christensen, et al.
Neurology|October 1, 1982
Lecithin administration in Alzheimer dementiaM W Dysken, P Fovall, C M Harris, et al.
Biological Psychiatry|September 1, 1990
Rapid dynamic CT scanning in primary degenerative dementia and age-matched controlsM W Dysken, M J Nelson, K M Hoover, et al.
Biological Psychiatry|April 1, 1984
Development of tolerance to neuroleptic-induced decreases in blink rateK T Mueser, M W Dysken, S Sussman, et al.
The Journal of Clinical Psychiatry|October 1, 1981
The pharmacokinetics of psychotropic medication in the elderly: a reviewR Hicks, M W Dysken, J M Davis, et al.
The American Journal of Psychiatry|October 1, 1979
Serial postdexamethasone cortisol levels in a patient undergoing ECTM W Dysken, G N Pandey, S S Chang, et al.
Journal of Clinical Psychopharmacology|August 1, 1982
Bioavailability of intramuscular versus oral haloperidol in schizophrenic patientsC B Schaffer, A Shahid, J I Javaid, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
JAMA|May 11, 1979
Drug interaction between ascorbic acid and fluphenazineM W Dysken, R J Cumming, R A Channon, et al.
Journal of Geriatric Psychiatry and Neurology|January 1, 1990
Hydergine treatment and psychophysiological measures in primary degenerative dementiaM A Kuskowski, G Morley, S M Malone, et al.
Psychopharmacology Bulletin|January 1, 1983
Neuroleptic concentrations in schizophrenic patients: measurements by radioreceptor assay and gas chromatographyJ I Javaid, J M Davis, M W Dysken, et al.
Hospital & Community Psychiatry|November 1, 1988
A multidisciplinary approach to primary degenerative dementiaA Frances, M W Dysken, R Christensen, et al.
Neurology|October 1, 1982
Lecithin administration in Alzheimer dementiaM W Dysken, P Fovall, C M Harris, et al.
Biological Psychiatry|September 1, 1990
Rapid dynamic CT scanning in primary degenerative dementia and age-matched controlsM W Dysken, M J Nelson, K M Hoover, et al.
Biological Psychiatry|April 1, 1984
Development of tolerance to neuroleptic-induced decreases in blink rateK T Mueser, M W Dysken, S Sussman, et al.
The Journal of Clinical Psychiatry|October 1, 1981
The pharmacokinetics of psychotropic medication in the elderly: a reviewR Hicks, M W Dysken, J M Davis, et al.
The American Journal of Psychiatry|October 1, 1979
Serial postdexamethasone cortisol levels in a patient undergoing ECTM W Dysken, G N Pandey, S S Chang, et al.
Journal of Clinical Psychopharmacology|August 1, 1982
Bioavailability of intramuscular versus oral haloperidol in schizophrenic patientsC B Schaffer, A Shahid, J I Javaid, et al.
Pageof 7